Lynparza, First In A New Class Of Cancer Drugs, Is Surprisingly Active In A ...

ForbesLynparza, First In A New Class Of Cancer Drugs, Is Surprisingly Active In A ...ForbesAt the recent American Association of Cancer Research (AACR) meeting, one of the most encouraging sets of presentations pertained to PARP inhibitors. What's emerging is that this new class of drugs, once considered of limited benefit and primarily for ...and more »

Share this post